RTW BIOTECH OPPORTUNITIES LTD financials
RTW BIOTECH OPPORTUNITIES LTD
549300Q7EXQQH6KF7Z84 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Other income | $2.4M | $1.5M |
| Administrative expenses | $808.5K | $749.6K |
| Profit for the year | $245.2M | $34.2M |
| Cash flow statement | ||
| Net cash from operating activities | $105.3M | -$124.3M |
| Net cash from financing activities | -$12.6M | $97.1M |
| Balance sheet | ||
| Total assets | $1.07B | $760.0M |
| Cash & equivalents | $6.0M | $5.4M |
| Non-controlling interests | $64.3M | $25.7M |
| Derived metrics | ||
| Cash conversion ratio | 0.43× | -3.64× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Assets | -$206.1K | $1.7M |
| Adjustments For Fair Value Gains Losses | -$59.4M | $34.5M |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | $15.2M | $8.2M |
| Auditors Remuneration For Audit Services | $352.3K | $367.0K |
| Current Accrued Expenses and Other Current Liabilities | $810.8K | $850.9K |
| Derivative Financial Assets | $146.8M | $110.2M |
| Derivative Financial Liabilities | $2.6M | $7.8M |
| Directors Remuneration Expense | $308.8K | $262.5K |
| Dividends Classified As Expense | $1.6K | $0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -$1.6M | $99.3K |
| Expense By Nature | $20.8M | $16.9M |
| Financial Assets At Fair Value | $794.3M | $611.0M |
| Financial Liabilities At Fair Value | $160.6M | $95.2M |
| Gains Losses On Change In Fair Value of Derivatives | $48.9M | $41.1M |
| Gains Losses On Disposals of Investments | $108.0M | $28.0M |
| Interest Expense | $7.1M | $4.8M |
| Investment Income | $34.6M | $8.2M |
| Liabilities | $203.8M | $127.4M |
| Net Assets Liabilities | $865.2M | $632.6M |
| Other Assets | $1.4M | $1.2M |
| Other Expense By Nature | $1.1M | $887.5K |
| Payments To Acquire Or Redeem Entitys Shares | $12.6M | $11.3M |
| Proceeds From Issuing Shares | $0 | $108.4M |
| Professional Fees Expense | $1.6M | $1.4M |
| Revenue From Dividends | $25.1M | $391.0K |
| Revenue From Interest | $7.0M | $6.3M |
Every line item above is a fact tagged in RTW BIOTECH OPPORTUNITIES LTD's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.